The psychoactive substance ibogaine is being investigated for treating several mental health disorders and substance abuse.

The man had sought out the drug to help him overcome his substance abuse disorder. Though anecdotal reports indicate potential promise, there's been no large-scale clinical trials on ibogaine's safety and efficacy. The plant is derived from a root bark named iboga and has been used for centuries by indigenous communities in Gabon, but first entered scientific consciousness in 1901 after its alkaloid was isolated from Iboga.

Although the substance is banned in the US, it's legal in Mexico. Americans who have traveled there for treatment, including the NFL's Braden Smith, say the drug helps deal with conditions like obsessive-compulsive disorder.

Scientists are investigating psilocybin, ketamine, LSD, and MDMA (also known as ecstasy) as potential treatments for mental health issues. These drugs enable an altered state of consciousness, which can have beneficial or harmful impacts depending on the nature of the experience. Research suggests these drugs can be effective in treating substance use disorders, mental health conditions, including depression and anxiety, and psychiatric disorders, including schizophrenia.

This article explores whether the therapeutic potential of psychedelic drug use is really as good as current research suggests. Scientists are exploring its applications for conditions ranging from the existential crisis that can accompany terminal diagnoses to chronic mental health conditions, including anxiety and PTSD.

Proponents say this short-acting psychedelic, formally known as dimethyltryptamine, could be particularly promising for medicinal use because longer-acting psychedelics can sideline someone for hours after a treatment with hallucinations. DMT is the primary psychoactive ingredient in ayahuasca, a psychoactive brew used across various South American cultures for spiritual, social, and medicinal purposes.

How magical are magic mushrooms, at least where depression is concerned? Some 24 volunteers participated in a study to evaluate the efficacy of using psilocybin in combination with psychotherapy to treat individuals suffering from depression. While some controversies remain about its use—psilocybin is known to cause psychosis sometimes—some scientists think the benefits outweigh the risks.

In this video, Michael Pollan, author of "This Is Your Mind On Plants," underscores the gaps in existing understanding about the substances and recommends only taking guided experiences, for safety and help. He tackles how psychedelics work, explains microdosing and psychedelic risks, how the substances could be used to treat addiction, and the history of psychedelic stigma.

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

Animal studies involving microdoses of psilocybin, the psychoactive component in magic mushrooms and ketamine, found it helped to alleviate anxiety and inflammation, an immune response that can cause damage when chronically active. Human studies are ongoing. In at least one double-blind study, where researchers and patients don't know who got a placebo versus the real thing, about half of the participants incorrectly guessed they had been given placebos.

Within seconds of inhaling a high dose of vaporized synthetic 5-MeO-DMT—a lab-produced substance that otherwise is naturally derived from the glands of the Colorado River toad—it induced slow brain waves. Such waves are typically associated with unconsciousness due to a coma or anesthesia, perhaps explaining why users describe feeling like everything falls away. The compound is currently in clinical trials for treating depression.

The country green lighted the treatments for July 1, 2023, onward, with MDMA—ectasy—as a post-traumatic stress disorder treatment, and psilocybin—magic mushrooms—as an option for people with treatment-resistant depression.

A 2006 study into the potential therapeutic benefits of psychedelics sparked a renewed interest in the field of psychedelic research, a development that has cascaded into commercialized ventures and experiences. This article details how growing research into the psychological benefits of psychedelics is matched by the rise of anecdotal reports, book deals, businesses, and corporate claims seeking to capitalize on psychedelic potential.

Brain imaging shows that ayahuasca, MDMA, DMT, and psilocybin profoundly affect neural activity, giving rise to higher states of introspection and consciousness. This article details exactly how each of these drugs physically affects the brain and what that means for mental health treatment. Some of these drugs quiet the brain or trigger the release of neurochemicals associated with mood regulation and learning.

Researchers have determined that LSD, taken in a medical setting, decreases anxiety related to "life-threatening disease," reduces brain reactivity to fearful faces, increases the meaning and emotional response derived from music, and more. No complications of LSD administration have been observed in medical settings, though acute adverse effects, including exhaustion, nausea, and difficulty concentrating.

As the use of recreational psychedelics became common, authorities were quick to claim LSD had lasting adverse effects, criminalizing the drug and halting scientific study for decades. Over time, LSD's reputation shifted from a potential source of enlightenment to a dangerous drug that could dim a person's future, and back to a possible therapeutic compound.

This "60 Minutes" episode from 2025 follows nine veterans attending a week-long psychedelic retreat to treat their PTSD. Most of the vets say the experience at the Mexican clinic was life-changing. But results were mixed: One veteran reported he was scared and that the experience worsened his mental health overall.

Psychedelics have made their way into the world of licensed mental healthcare, and the drugs have been proven to help people process and lessen anxiety and depression. What does this mean for people with terminal illnesses who are afraid of death?

Psychedelics' modern era began when LSD was discovered in the 1930s. By the 1950s, clinical trials were underway. US user experimentation outside of medical settings (and high-profile violence, like the Manson murders) inspired negative attitudes toward psychedelics, leading to use restrictions that prohibited companies from patenting psychedelic compounds. This strangled psychedelics' profitability until the 1990s when the government loosened its grip and psychedelics research began seeing a resurgence.

Dr. Roland Griffiths helped lead the revival of psychedelic research, often prescribing the use of psilocybin to address severe depression or anxiety in patients. This podcast explores how Griffiths leaned on his own career after being diagnosed with cancer and facing the prospect of death.

With a checkered history of misconduct, how will psychedelic-assisted therapists be held accountable in the emerging legal field? This article explores the nascent field's need for ethical guidelines and clear protection of patient rights when therapeutic breakthroughs teeter "on the edge of consent."

Individuals with this mental health condition are routinely eliminated from any psychedelic research due to concerns about triggering or worsening psychosis. Yet there is little high-quality research in this area, raising questions about if further research into this question is warranted as interest grows in using psychedelics for therapeutic purposes.

After decades of repression, psychedelic research is making a resurgence. Hear from a host of experts in this 20-minute video on what that could mean for the future of mental health. The current science on psychedelics believes LSD can cause a particular brain network to quiet or deactivate.

The answer is usually more complicated than a simple yes or no. This resource includes a state-by-state and international breakdown of current psychedelics legislation and reform. As of November 2023, psychedelics are fully illegal in 18 states, though there still may be religious or medical exemptions depending on the drug in question. Legislation reform and decriminalization efforts are ongoing.

Since symptoms like hallucinations were believed be due to an imbalance of black bile, yellow bile, blood, and phlegm, the treatment at the time was to bring those humors back into balance. That meant standard treatments could include bleeding a patient or using substances like hellebore to induce vomiting or diarrhea.

LSD and psilocybin have shown promise as antidepressants. Using a virtual library of similar chemical compounds, researchers determined via animal studies that two molecules inspired by LSD have antidepressant effects without any associated hallucinogenic experience. These molecules were found to be 40 times more potent than the common antidepressant fluoxetine, also known as Prozac, with antidepressant effects lasting up to 21 days.

Psychedelics produce powerful emotions in its users, including a profound sense of meaningfulness. The philosopher William James called this sense "noetic" in the late 19th century, but for decades researchers avoided studying the effects of such drugs on the brain. However, the recent resurgence in psychedelic research has heightened interest in the relationship between this noetic sense resulting from the therapeutic use of drugs. Learn what researchers have found out here.

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

In the 1960s, Captagon was patented in Germany as a stimulant similar to amphetamines. It was prescribed for a time to address narcolepsy, ADHD, and other conditions. As its addictiveness and psychosis-inducing quality became more apparent, the drug has been banned in many countries. A robust illicit manufacturing of the drug endures in the Middle East, especially in Syria and Lebanon. Track locations where the drug has been seized on this updated map.

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

Within a decade of LSD's discovery, the US government had launched a secret initiative involving hypnosis and hallucinogens. LSD researcher Louis Jolyon West conducted experiments for the CIA's MKUltra project, which focused on the potential of mind control. He later took part in a criminal trial that hinged on testimony whose sourcing was seemingly inspired by MKUltra experiments. This article explores light shed by West's personal archive.

After centuries of use by Mexican spiritual healers, Salvia divinorum is surging in popularity in the U.S. — and the government has taken notice.

Consumer Reports, which tests supplements for safety, urges consumers to avoid these four supplements due to safety warnings from researchers and public health authorities.

Researchers report that virtual reality and psychedelics may be leave users with similar insights and therapeutic benefits. Try out this free psychedelic virtual reality experience to see if this holds true for you. According to the program’s creators, a study into the efficacy of this 45-minute experience indicates it may help alleviate symptoms of mild to moderate depression.

An agency committee assessed if this approach could have undesirable ripple effects across multiple generations and whether a clinical trial involving this approach would be appropriate. As of 2026, the US has continued to prohibit this procedure though it is legal in other settings including the UK and Australia.